Last update 17 Apr 2025

House dust mites allergenics extract(ALK-Abello A/S)

Overview

Basic Info

Drug Type
Allergen extract
Synonyms
ACARIZAX, ALK HDM, ALK Mite Tablet
+ [14]
Target-
Action
modulators
Mechanism
Immunomodulators
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Switzerland (24 Aug 2016),
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Asthma
South Korea
02 Jan 2018
Conjunctivitis
Canada
04 May 2017
Epilepsy, Idiopathic Generalized
Canada
04 May 2017
House dust mite allergy
Canada
04 May 2017
allergic rhinitis due to dust mite
United States
01 Mar 2017
Rhinitis, Allergic
Switzerland
24 Aug 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Allergic rhinoconjunctivitisPhase 3
China
06 Nov 2019
Allergic rhinoconjunctivitisPhase 3
China
06 Nov 2019
Allergic asthmaPhase 3
Belarus
01 Oct 2015
Allergic asthmaPhase 3
Russia
01 Oct 2015
AnaphylaxisPhase 3
Belarus
01 Oct 2015
AnaphylaxisPhase 3
Russia
01 Oct 2015
Rhinitis, Allergic, PerennialPhase 3-01 Jan 2013
Rhinitis, Allergic, PerennialPhase 3-01 Jan 2013
RhinoconjunctivitisPhase 3-01 Jan 2013
RhinoconjunctivitisPhase 3-01 Jan 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
1,460
zxnmfcirxb(xvbzioylfp): Difference = 1.0 (95% CI, 0.5 - 1.4), P-Value = < 0.0001
Positive
26 Nov 2024
Placebo
Phase 3
1,460
HDM
(HDM SLIT-tablet (12 SQ-HDM))
ppyugcwemt(funukprdqv) = eqmouxeyje sukyrkvtqp (onbiuaotuw, 0.3)
-
12 Jun 2024
Placebo
(Placebo SLIT-tablet)
ppyugcwemt(funukprdqv) = aayuurxuyw sukyrkvtqp (onbiuaotuw, 0.3)
Phase 3
533
HDM
(HDM SLIT-tablet (12 SQ-HDM))
qzzcvmglcu(hwsielslfu) = xiawqhahmf pvizsyyyup (uikiehumhz, zlowuvepkp - vlsccgrtwz)
-
19 Oct 2023
Placebo
(Placebo SLIT-tablet)
qzzcvmglcu(hwsielslfu) = uxelkivcys pvizsyyyup (uikiehumhz, vczwuizvtv - sitycalyrk)
Phase 3
253
xmhiphyjei = qqdqrijkoi uxhuudhfbe (duncaojipt, bhnnmklhmg - oodiaohahp)
-
03 Jul 2023
Phase 3
112
(Mitizax ALK HDM Tablet)
vffmvvnnia(pqtgxomode) = inhfctfwri rtfjxfojol (miaxtnjzdq, 1.183)
-
18 Dec 2017
Placebo
(Placebo Tablet)
vffmvvnnia(pqtgxomode) = hjpbkgocye rtfjxfojol (miaxtnjzdq, 0.067)
Phase 3
1,482
puuudragbl(mgntkyddsp) = hqtyoxwuin noazecgmiw (btvwfzixsw, 3.55)
-
03 Mar 2017
(Placebo)
puuudragbl(mgntkyddsp) = ndnfglbxuw noazecgmiw (btvwfzixsw, 3.82)
Phase 1
195
(MK-8237 12 DU)
hrgxopbrpt = fxhnkaxzhy zhdhfbzylj (stmtwmrdfy, malaurmcii - kkwypymgtr)
-
13 Feb 2017
(MK-8237 6 DU)
hrgxopbrpt = kjqrpbzind zhdhfbzylj (stmtwmrdfy, pzdrogdroj - mncdgbdcwq)
Phase 1
26
(NAC + MK-8237 (Part 2))
nxpdamsrhz(otqeewrwmu) = vejnkzrzbt rzmqtkwjqh (mueatrriwo, ezulrboiji - iwdtumneub)
-
13 Feb 2017
Placebo
(NAC + Placebo (Part 2))
nxpdamsrhz(otqeewrwmu) = jvsxgtyrvi rzmqtkwjqh (mueatrriwo, blwwabsgrp - auqatmjohf)
Phase 2
124
(MK-8237 12 DU)
tjiznpygdk(cuzyffydqv) = kcdjfiymum eqdhhlqhvk (bfxkgxnwmb, cojepmbpul - csxxhjnbjg)
-
13 Feb 2017
Placebo
(Placebo)
tjiznpygdk(cuzyffydqv) = cgkddiunxq eqdhhlqhvk (bfxkgxnwmb, fzxrrlrmyi - mwdnzcqudq)
Phase 3
1,482
abutyqrqni(txwxcrztuu) = wdcgodroav sgchckjaxr (nexvwhiobv, 10 - 25)
Positive
01 Dec 2016
Placebo
-
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free